hypothyroidism and glp-1 medication with Hashimoto's Disease: Safety Monitoring Guide – Bolt Pharmacy Implications of GLP-1 Receptor Agonist

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis

The number of participants using sodium-glucose cotransporter-2 (SGLT2) inhibitors was low at baseline (15%), but that number increased during the trial

Most of these medications are administered via subcutaneous injection, with dosing frequencies ranging from daily to once weekly depending on the specific agent

The researchers found that all semaglutide doses were generally well tolerated with no new safety concerns

These data suggest that YM does not directly stimulate GLP-1 production in L-cells and may require alternative pathways or intermediates to exert its effects